Business Description
Regenxbio Inc
NAICS : 325412
SIC : 2836
ISIN : US75901B1070
Description
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.04 | |||||
| Equity-to-Asset | 0.58 | |||||
| Debt-to-Equity | 0.28 | |||||
| Debt-to-EBITDA | -0.39 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -2.21 | |||||
| Beneish M-Score | -3.42 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -20.8 | |||||
| 3-Year EBITDA Growth Rate | -28.2 | |||||
| 3-Year EPS without NRI Growth Rate | -25.6 | |||||
| 3-Year FCF Growth Rate | -34 | |||||
| 3-Year Book Growth Rate | -11.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 44.44 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 19.09 | |||||
| 9-Day RSI | 28.51 | |||||
| 14-Day RSI | 34.39 | |||||
| 6-1 Month Momentum % | -18.18 | |||||
| 12-1 Month Momentum % | -49.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.05 | |||||
| Quick Ratio | 3.05 | |||||
| Cash Ratio | 2.49 | |||||
| Days Sales Outstanding | 13.24 | |||||
| Days Payable | 212.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.5 | |||||
| Shareholder Yield % | -34.42 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 54.36 | |||||
| Operating Margin % | -289.09 | |||||
| Net Margin % | -283.19 | |||||
| FCF Margin % | -219.38 | |||||
| ROE % | -69.61 | |||||
| ROA % | -40.81 | |||||
| ROIC % | -82.62 | |||||
| ROC (Joel Greenblatt) % | -125.82 | |||||
| ROCE % | -49.72 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 4.2 | |||||
| PB Ratio | 1.22 | |||||
| Price-to-Tangible-Book | 1.22 | |||||
| EV-to-EBIT | -0.83 | |||||
| EV-to-Forward-EBIT | -67.68 | |||||
| EV-to-EBITDA | -0.89 | |||||
| EV-to-Forward-EBITDA | 19.59 | |||||
| EV-to-Revenue | 2.3 | |||||
| EV-to-Forward-Revenue | 0.75 | |||||
| EV-to-FCF | -1.05 | |||||
| Price-to-Net-Current-Asset-Value | 3.83 | |||||
| Price-to-Net-Cash | 9.79 | |||||
| Earnings Yield (Greenblatt) % | -120.48 | |||||
| FCF Yield % | -50.39 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Regenxbio Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 77.254 | ||
| EPS (TTM) (€) | -4.601 | ||
| Beta | 1.96 | ||
| Volatility % | 92.52 | ||
| 14-Day RSI | 34.39 | ||
| 14-Day ATR (€) | 0.386149 | ||
| 20-Day SMA (€) | 8.675 | ||
| 12-1 Month Momentum % | -49.44 | ||
| 52-Week Range (€) | 7.05 - 23.6 | ||
| Shares Outstanding (Mil) | 49.55 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Regenxbio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Regenxbio Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Regenxbio Inc Frequently Asked Questions
What is Regenxbio Inc(FRA:RB0)'s stock price today?
The current price of FRA:RB0 is €7.05. The 52 week high of FRA:RB0 is €23.60 and 52 week low is €7.05.
When is next earnings date of Regenxbio Inc(FRA:RB0)?
The next earnings date of Regenxbio Inc(FRA:RB0) is 2025-02-27 Est..
Does Regenxbio Inc(FRA:RB0) pay dividends? If so, how much?
Regenxbio Inc(FRA:RB0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers